Author(s)

Tchamdja Toyi^1*, Djalogue Lihanimpo¹, Kodjo Kossi², Ganu Koudjo², Kaaga Laconi Yéba², Mossi Komi Edem², M’bortché B. Kodjo², Djibril Mohaman Awalou², Balaka Abago²

¹Internal Medicine Departement, University de Kara, Kara, Togo.
²Internal Medicine Departement, Université of Lomé, Lomé, Togo.

Introduction. Hyperprolactinemia represents a supraphysiological secretion of prolactin. In clinical practice, it is the most frequently encountered anterior pituitary disorder. However, its real prevalence is little known in Africa. The purpose of this study is to list all cases of hyperprolactinemia over the past four years and to make an inventory of the various etiologies found and their management. Methodology. This is a cross-sectional descriptive study on the files of patients who came for consultation in the internal medicine and endocrinology department with hyperprolactinemia retrospectively collected from January 2017 to December 2020. Included were patients followed or whose the diagnosis of hyperprolactinemia was established in endocrinological consultation during the study period. Results. This study recorded 26 cases of hyperprolactinemia. The female sex represented 73.08% (sex ratio M/F 0.37) and the average age was 33.92 years. The 40 - 50 age group was the most represented with 30.77%. In women, galactorrhea accounted for 73.07%, amenorrhea 57.69% of clinical pictures and infertility 23.08%. In men, infertility accounted for 7.69% of presentations, gynecomastia 11.54% and erectile dysfunction 15.38%. The duration of evolution of the signs was 4 months in 23.08% of the patients. The mean prolactinemia was 702.58 ng/ml. CT was performed in 80.85% of patients. The main etiologies were pituitary adenomas (77%). All our patients were treated with dopaminergic agonists. Cabergoline was prescribed in 77% of patients. The evolution was favorable in 96.25% of patients. Conclusion. Hyperprolactinemia is a pathology that exists in our regions. The main etiology remains pituitary adenomas and treatment with cabergoline.

Hyperprolactinemia, Hospital Environment, CHU SO, Togo

Toyi, T. , Lihanimpo, D. , Kossi, K. , Koudjo, G. , Yéba, K. , Edem, M. , Kodjo, M. , Awalou, D. and Abago, B. (2024) Hyperprolactinemia in Hospitals in Lomé: Diagnostic and Therapeutic Aspects. Open Journal of Internal Medicine, 14, 43-52. doi: 10.4236/ojim.2024.141004.